Atara Biotherapeutics Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Atara Biotherapeutics stock.
View analyst ratings for Atara Biotherapeutics or view top-rated stocks.

Wall Street analysts have given Atara Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Atara Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Atara Biotherapeutics.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its earnings results on Sunday, August, 8th. The biotechnology company reported ($0.91) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.88) by $0.03. The biotechnology company earned $3.87 million during the quarter, compared to analysts' expectations of $6.32 million.
View Atara Biotherapeutics' earnings history.

Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ATRA stock has increased by 61.4% and is now trading at $16.08.
View which stocks have been most impacted by COVID-19.

7 equities research analysts have issued twelve-month price objectives for Atara Biotherapeutics' stock. Their forecasts range from $27.00 to $41.00. On average, they expect Atara Biotherapeutics' stock price to reach $31.33 in the next twelve months. This suggests a possible upside of 94.9% from the stock's current price.
View analysts' price targets for Atara Biotherapeutics or view top-rated stocks among Wall Street analysts.

6 employees have rated Atara Biotherapeutics CEO Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among Atara Biotherapeutics' employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Atara Biotherapeutics include Kodiak Sciences (KOD), Sana Biotechnology (SANA), Abcam (ABCM), Recursion Pharmaceuticals (RXRX), Editas Medicine (EDIT), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), SpringWorks Therapeutics (SWTX), Allogene Therapeutics (ALLO), Bavarian Nordic A/S (BVNRY), Relay Therapeutics (RLAY), Kymera Therapeutics (KYMR), Translate Bio (TBIO), BioCryst Pharmaceuticals (BCRX) and Soaring Eagle Acquisition (SRNG).
View all of ATRA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Atara Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.18%), Maverick Capital Ltd. (9.09%), JPMorgan Chase & Co. (8.94%), Vanguard Group Inc. (7.91%), Redmile Group LLC (7.61%) and State Street Corp (5.16%). Company insiders that own Atara Biotherapeutics stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends for Atara Biotherapeutics.

ATRA stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Credit Suisse AG, Redmile Group LLC, Bridger Management LLC, Healthcare of Ontario Pension Plan Trust Fund, FMR LLC, Alberta Investment Management Corp, and Morgan Stanley. Company insiders that have sold Atara Biotherapeutics company stock in the last year include Amar Murugan, Jakob Dupont, Joe Newell, Pascal Touchon, Thomas Peterffy, and Utpal Koppikar.
View insider buying and selling activity for Atara Biotherapeutics or view top insider-selling stocks.

ATRA stock was acquired by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., JPMorgan Chase & Co., BlackRock Inc., Goldman Sachs Group Inc., 683 Capital Management LLC, Renaissance Technologies LLC, Wasatch Advisors Inc., and Vanguard Group Inc..
View insider buying and selling activity for Atara Biotherapeutics or or view top insider-buying stocks.

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ATRA stock can currently be purchased for approximately $16.08.

Atara Biotherapeutics has a market capitalization of $1.36 billion. The biotechnology company earns $-306,620,000.00 in net income (profit) each year or ($4.15) on an earnings per share basis.

Atara Biotherapeutics employs 437 workers across the globe.

The official website for Atara Biotherapeutics is www.atarabio.com.

Atara Biotherapeutics is headquartered at 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080.

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at (650) 278-8930 or via email at [email protected]